Pluri congratulates Mesoblast, CEO on FDA approval of MSC-based therapy

Pluri (PLUR) congratulates Mesoblast and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease. This landmark achievement marks a moment in the advancement of regenerative medicine and highlights the growing clinical and regulatory recognition of MSC therapies’ transformative potential. “This milestone is not just a triumph for Mesoblast, but for the entire field of cellular medicine,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “Silviu and the team at Mesoblast have opened a new chapter in harnessing MSC therapies to treat devastating conditions like SR-aGVHD.”